XERS - Xeris Pharmaceuticals GAAP EPS of -$0.25 in-line net product revenue of $21.91M misses by $1.48M

Xeris Pharmaceuticals press release (NASDAQ:XERS): Q1 GAAP EPS of -$0.25 in-line. Net Product Revenue of $21.91M (+172.2% Y/Y) misses by $1.48M. Cash, cash equivalents, and short-term investments at March 31, 2022 was $132.1 million compared to $102.4 million at December 31, 2021. Affirming 2022 guidance for combined net product revenues of $105M - $120M vs consensus of $113.88M, $50M in synergies, 2022 year-end cash balance of $90M-$110M, and cash flow breakeven by year-end 2023

For further details see:

Xeris Pharmaceuticals GAAP EPS of -$0.25 in-line, net product revenue of $21.91M misses by $1.48M